Announcement • Aug 03
InSilico Medicine Cayman TopCo Receives NMPA IND Approval for ISM8969/HT-001, Blood-Brain-Barrier-Penetrant NLRP3 Inhibitor Co-Developed with Hygtia Therapeutics Co., Ltd InSilico Medicine Cayman TopCo announced that, ISM8969/HT-001, an innovative oral NLRP3 inhibitor co-developed with Hygtia Therapeutics Co., Ltd, has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) of China for the treatment of Parkinson’s disease. Following the announcement of first-in-human dosing in Australia under the Phase I study in June 2026, this approval marks the official launch of parallel clinical evaluations in China and Australia. The clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ISM8969/HT-001 in healthy subjects and preliminary efficacy of ISM8969/HT-001 in patients with Parkinson's disease, establishing a foundation for its subsequent clinical development. In preclinical evaluation studies, ISM8969/HT-001 exhibited a balanced druggability profile, with promising in vitro activity and safety, favorable in vivo PK/PD profile, as well as efficacy against inflammation in multiple mouse disease models, including acute inflammatory disease and chronic disease models. Compared with other clinically advanced peripherally restricted NLRP3 inhibitors, ISM8969/HT-001 is blood-brain-barrier (BBB)-penetrant and can access the central nervous system, enabling potential treatment of neuroinflammation-related diseases. ISM8969/HT-001 is an orally available, BBB-penetrant NLRP3 inhibitor discovered using Insilico Medicine’s generative AI platform Chemistry42, which has demonstrated strong efficacy, favorable safety, and robust BBB-penetration profile in preclinical studies. Since its nomination as a Preclinical Candidate Compounds in December 2024, ISM8969/HT-001 has rapidly advanced through clinical development: receiving the IND clearance from the U.S. Food and Drug Administration and announcing a co-development partnership with Hygtia Therapeutics in January 2026; completing first-in-human dosing in Australia of Phase I clinical study in June 2026 as its first clinical milestone; and receiving IND approval from China’s NMPA in July 2026. Live News • Jul 31
Insilico Medicine Unveils Standardized AI Benchmarking Service for Drug Discovery Insilico Medicine Cayman TopCo has launched what it describes as the industry's first Drug Discovery and Development Benchmark as a Service, offering a standardized framework to evaluate frontier AI and foundation models on real-world drug discovery tasks across medicinal chemistry, synthesis, disease biology, clinical development and longevity research.
The DDD Benchmark is designed to distinguish genuine AI-driven drug discovery capability from models that rely on memorized test answers, with both private assessments for clients and a public leaderboard intended to create transparent, comparable performance metrics.
The stock last traded at HK$45.70, with a return of 21.6% year to date.
A standardized real-world benchmark could matter for Insilico Medicine because it may help position its own AI tools against rivals on objective criteria while also drawing industry participants onto its platform. The main risk is whether external users and large pharma companies adopt the benchmark widely enough for it to become a reference standard rather than just another internal tool. Announcement • Jul 31
Insilico Medicine Launches Drug Discovery and Development Benchmark as A Service Insilico Medicine announced the launch of the Drug Discovery and Development (DDD) Benchmarks as a Service (BaaS). It is a pioneering standardized evaluation framework anchored in carefully decontaminated real-world data and proprietary validated programs for measuring how frontier AI and foundation models built on other architectures perform on real-world tasks across medicinal chemistry, chemical synthesis, disease biology, clinical development, and longevity research. Insilico's BaaS is available to any organization developing frontier AI for drug discovery or leveraging foundation models in their research. The DDD Benchmark provides an independent, real-world measure of how a model performs. The DDD Benchmark comprises two complementary evaluation suites: Drug Discovery Foundations includes more than 300 evaluations built from proprietary out-of-distribution test sets and rigorously decontaminated public data. It measures a model's core competencies across the discipline — spanning disease biology, molecular property prediction and optimization, retrosynthesis, structure-based design, and clinical development. Drug Candidate Essentials evaluates a model's ability to navigate an end-to-end drug discovery program, from hit identification through preclinical candidate (PCC) nomination. Its reference baselines are anchored in Insilico's own validated programs, testing whether a model can make the sequential, high-stakes decisions that real drug discovery demands. Benchmarking is straightforward: any model served through a standard chat-completions API can be evaluated by contacting Insilico Medicine. Insilico Medicine scores the resulting outputs against expert reference baselines and provides a standardized scorecard comparing performance with leading models. Results are delivered with a verified score report that lets organizations certify performance for internal and partner audiences. Organizations seeking public recognition can also publish their results on the DDD Benchmark public leaderboard, giving the field a transparent, like-for-like view of model capability. The DDD Benchmark is designed to measure whether those capabilities translate into sound, real-world drug discovery decisions rather than strong performance on abstract tasks. The DDD Benchmark builds on Insilico's Pharma.AI platform and the MMAI Gym, the company's post-training environment for scientific AI. Since its founding, Insilico has nominated 31 preclinical candidates, received over 10 investigational new drug (IND) clearances, and compressed the timeline to PCC nomination to roughly 12 to 18 months, compared with the 2.5 to 4-plus years typical of traditional drug discovery. Its lead program, Rentosertib (ISM001-055), is a first-in-class, AI-discovered and AI-designed TNIK inhibitor now in Phase III development for IPF. The DDD Benchmark as a Service is available now. 
